^
BIOMARKER:

HER-2 mutation

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
HER-2 mutation
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Cervical Cancer
neratinib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Lung Cancer
trastuzumab + pertuzumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
afatinib
Resistant
:
A2
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab
Resistant
:
A2
HER-2 mutation
Non Small Cell Lung Cancer
ado-trastuzumab emtansine
Sensitive
:
A2
HER-2 mutation
Solid Tumor
BDTX-189
Sensitive
:
B
HER-2 mutation
Breast Cancer
ribociclib
Sensitive
:
B
HER-2 mutation
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Solid Tumor
tarloxotinib bromide
Sensitive
:
C2
HER-2 mutation
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive
:
C2
HER-2 mutation
Gastric Cancer
pyrotinib
Sensitive
:
C2
HER-2 mutation
Lung Cancer
pyrotinib
Sensitive
:
C2
HER-2 mutation
Urothelial Cancer
afatinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
tarloxotinib bromide
Sensitive
:
C2
HER-2 mutation
Solid Tumor
pyrotinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
pyrotinib
Sensitive
:
C2
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab
Sensitive
:
C2
HER-2 mutation
Breast Cancer
neratinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab + neratinib
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
neratinib + temsirolimus
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
U3-1402
Sensitive
:
C3
HER-2 mutation
Biliary Tract Cancer
neratinib
Sensitive
:
C3
HER-2 mutation
Lung Adenocarcinoma
trastuzumab + pertuzumab
Sensitive
:
C3
HER-2 mutation
Squamous Cell Carcinoma of Head and Neck
cetuximab + ISU104
Sensitive
:
C3
HER-2 mutation
Thymic Carcinoma
pyrotinib
Sensitive
:
C3
HER-2 mutation
Solid Tumor
KN046 + KN026
Sensitive
:
C3
HER-2 mutation
Colorectal Cancer
pyrotinib
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
PD-L1 inhibitor
Resistant
:
C3
HER-2 mutation
Lung Adenocarcinoma
afatinib
Sensitive
:
C3
HER-2 mutation
HER2 Positive Breast Cancer
trastuzumab
Resistant
:
C3
HER-2 mutation
Lung Adenocarcinoma
ado-trastuzumab emtansine
Sensitive
:
C3
HER-2 mutation
HER2 Positive Breast Cancer
neratinib
Sensitive
:
C3